Background/ObjectivesNon-small cell lung cancer (NSCLC) is a leading cause of cancer-related death globally. Resistance to third-generation epidermal growth Abstract Background/Objectives: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death globally. Resistance to third-generation epidermal growth factor receptor...
Open AccessArticle Predicting Lifetime Risk of Kidney Failure Using Age and a Single eGFR Measurement by Ryo EnokiRyo Enoki SciProfiles Scilit Preprints.org Google Scholar 1,*, Mariko MiyazakiMariko Miyazaki SciProfiles Scilit Preprints.org Google Scholar 1, Enyu ImaiEnyu Imai SciProfiles Scilit Preprints.org...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and often fatal cancer with limited treatment options. Small nucleolar RNA host gene 10 (SNHG10) has emerged as a key regulator in the progression and metastasis of human cancers. However, the potential of...
Background Many factors cause kidney transplant graft failure. To identify at-risk patients and tailor treatment, failure risks must be accurately predicted. We are trying to predict the temporal progression of graft function (as treated with estimated glomerular filtration rate) using...
AbstractPurpose To evaluate the efficacy and safety of [177Lu]Lu-DOTA-IBA combined with maintenance EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC) and bone metastases. Methods In this prospective, single-center study, 52 patients with EGFR-mutated NSCLC and...
AbstractBackground Research on the efficacy of first-line osimertinib in non-small cell lung cancer (NSCLC) patients with different epidermal growth factor receptor (EGFR) exon 19 deletion (19del) mutation sites is limited. This study aimed to evaluate whether different EGFR 19del subtypes...
Abstract EGFR and HER2 are overexpressed in numerous malignancies, including breast cancer. A novel series of 1,2,3-triazole hybrids comprising quinoline-imidazole moieties was created as part of an ongoing endeavor to find new anticancer drugs targeting these proteins. Several analytical techniques,...
Osimertinib Combo Boosts PFS in EGFR/TP53+ NSCLC Trial Data from the phase 3 TOP trial support a potential molecular risk–guided treatment strategy for EGFR-mutant advanced NSCLC. Data from the phase 3 TOP trial (NCT04695925) demonstrated a significant progression-free survival (PFS)...
